This review systematically integrates advances in STAMBPL1 biology from structural to translational studies, highlighting its promise as a therapeutic target for precision cancer therapy.
Hu Lei, Han-Zhang Xu, Li Yang et al.· Molecular Biology Reports· 0 citations
Current advances in USP48 structure, substrate specificity, molecular mechanisms, and disease-specific functions are synthesized to provide a critical evaluation of preclinical USP48-targeted therapeutic strategies, and delineate the major conceptual and translational challenges impeding the clinical development of USP...
Hu Lei, Chujiao Zhu, Li Yang et al.· Biochemical and Biophysical...· 1 citation
YL064 is established as a promising ATXN3 inhibitor that targets the ubiquitin-proteasome pathway to exert anti-tumor effects, highlighting its potential as a novel therapeutic agent for ATXN3-driven cancers.
Zhenge Zhang, Wenhui Bai, Yayue Tan et al.· Cell Death & Disease· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.